Case Series: Sacubitril/Valsartan Role for Chemotherapy-Induced Cardiotoxicity: An in-Depth Investigation in Saudi Arabia

Abstract

Background

Chemotherapy-induced cardiotoxicity is a significant problem, ranking as the second most frequent cause of mortality in cancer patients. This adverse outcome encompasses many cardiovascular problems, such as heart failure. Sacubitril/valsartan has shown potential in the management of heart failure, however, its effectiveness in treating chemotherapy-induced heart failure has not been extensively explored. We performed a case series to investigate the safety and effectiveness of sacubitril/valsartan in treating chemotherapy-induced cardiomyopathy in Saudi Arabia.

Methods

The case series was conducted at a single medical center in Makkah, Saudi Arabia. The data gathered included patient demographics, clinical features, laboratory results, echocardiographic findings, and medication information. The data underwent analysis using descriptive statistics.

Results

Out of the total of eight patients who were part of the investigation, a notable majority of six individuals exhibited substantial enhancements in their ejection fraction (EF) after receiving sacubitril/valsartan medication.

Conclusion

Our case series provides significant insights by revealing improvements in ejection fraction (EF) in six out of eight patients who had chemotherapy-induced cardiomyopathy after receiving sacubitril/valsartan treatment.

Keywords:

• oncology
• sacubitril/valsartan
• cardiotoxicity
• chemotherapy
• Saudi Arabia

Data Sharing Statement

Upon reasonable request, the corresponding author is willing to provide the data.

Ethical Approval

The study obtained ethical clearance from the Biomedical Research Ethics Committee at Umm Al Qura University, with the assigned permission number HAPO-02-K-012-2023-03-1488. Stringent measures were used to ensure the preservation of confidentiality and anonymity of participants’ replies throughout the data-gathering procedure. In compliance with ethical standards and to ensure the protection of our participants’ privacy and rights, informed consent for publication was obtained from all individuals included in this case series. This process was conducted in accordance with the ethical guidelines of our institution and aligns with the principles of the Declaration of Helsinki. All personal identifiers have been removed or altered to protect patient privacy.

Author Contributions

Each author made significant contributions to this research, including involvement in conceptualization, study design, data acquisition, analysis, and interpretation. They also contributed to the drafting, revision, and critical review of the manuscript. All authors gave their final approval for the manuscript’s publication, selected the journal for submission, and committed to being accountable for all aspects of the research.

Disclosure

The authors have disclosed that they have no conflicts of interest that might potentially influence the research outcomes.

Additional information

Funding

This research was conducted independently without any external funding or financial support.